← Leaderboards
Gordon M Ringold
Quadriga Biosciences, Inc.
$6,041,839
Attributed
$6,041,839
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,041,839 · 2
By mechanism
R44$6,041,839 · 2
Top collaborators
No co-investigators on record.
Most similar at Quadriga Biosciences, Inc.
Same institution · by research overlap
- Kerry Jean Koller$1,986,820
Others in their field
Other Emerging Leaders on “Phase Iii Trial”
- Kimberly Smith · Ppd Development Lp$122,008,792
- Yunda Huang · Fred Hutchinson Cancer Center$52,249,798
- Susan Abushakra · Alzheon, Inc.$51,190,244
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$45,097,399
- Greg Yothers · University Of Chicago$25,122,895
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,144,108
Research focus
Phase Iii TrialRadiation TherapyProgression-Free SurvivalsPrimary EndpointSmall Business Innovation Research GrantTumorDiagnosisNeoplastic CellPharmaceutical PreparationsPreclinical StudyResponseSafetyCommercializationBiological SciencesBlood - Brain Barrier AnatomyDesignDoseFundingNormal Tissue MorphologyOperative Surgical ProceduresPhase Iii Clinical TrialsEnrollmentAnalogAmino Acid Transporter
Grant awards (6)
Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters$1,307,447
R44 · FY2025 · CA · contact PI
QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer$702,470
R44 · FY2024 · CA · contact PI
Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters$1,324,080
R44 · FY2023 · CA · contact PI
QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer$286,470
R44 · FY2023 · CA · contact PI
Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters$1,368,236
R44 · FY2021 · CA · contact PI
QBS10072S for the Treatment of Brain Metastatic Triple-Negative Breast Cancer$1,053,136
R44 · FY2021 · CA · contact PI